Document Detail

Atopaxar. A novel player in antiplatelet therapy?
MedLine Citation:
PMID:  22859265     Owner:  NLM     Status:  In-Data-Review    
Atopaxar, also known as E 5555 is a novel reversible protease-activated receptor-1 (PAR-1) thrombin receptor antagonist. To date, Atopaxar has been investigated in phase II trials with focus on safety and tolerability in patients with acute coronary syndromes or stable coronary artery disease on top of standard antiplatelet therapy. Atopaxar was generally well tolerated, however a rise in liver enzymes and prolongation of the QTcF interval were observed. The data suggest, that atopaxar administration may promote some minor bleeding complications, but does not seem to significantly increase the risk of major bleeding. Although not powered for efficacy, the currently available data suggest potential benefits in patients at high risk for recurrent ischemic events on top of standard antiplatelet therapy. In conclusion, more studies (e.g. phase III) are needed to evaluate efficacy and safety of atopaxar.
T Wurster; A E May
Related Documents :
2017225 - Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with o...
17511685 - Tacrolimus monotherapy without steroids after liver transplantation--a prospective rand...
23563735 - Treatment of the residual cavity during hepatic hydatidosis surgery: a cohort study of ...
23985435 - The anti-caries efficacy of a dentifrice containing 1.5% arginine and 1450ppm fluoride ...
25479065 - Low vitamin d level and impact on severity and recurrence of clostridium difficile infe...
22308625 - Promises and difficulties with the use of femoral intra-medullary lengthening nails to ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hämostaseologie     Volume:  32     ISSN:  0720-9355     ISO Abbreviation:  Hamostaseologie     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8204531     Medline TA:  Hamostaseologie     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  228-33     Citation Subset:  IM    
Prof. Andreas May, University Hospital Tübingen - Cardiology, Otfried-Müller-Str. 10, 72076 Tübingen, Germany, Tel. +49/(0)7071/2983160; Fax +49/(0)7071/294473, E-mail:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ptaquiloside-induced early-stage urothelial lesions show increased cell proliferation and intact ?-c...
Next Document:  Carbon dioxide as a carbon source in organic transformation: carbon-carbon bond forming reactions by...